United Therapeutics (UTHR) Capital Expenditures (QoQ) (2009 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Capital Expenditures (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn |
| 2 | AbbVie | 440.49 Bn | 433.92 Bn | 12.70 Bn |
| 3 | Merck | 365.81 Bn | 358.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.67 Bn | 258.98 Bn | 11.24 Bn |
| 5 | Pfizer | 158.99 Bn | 147.29 Bn | 10.94 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - |
| 8 | Incyte | 25.30 Bn | 20.77 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.54 Bn | 15.15 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.14% |
| Mar 31, 2026 | -41.70% |
| Dec 31, 2025 | -17.86% |
| Sep 30, 2025 | 238.42% |
| Jun 30, 2025 | -16.96% |
| Mar 31, 2025 | -13.61% |
| Dec 31, 2024 | 13.33% |
| Sep 30, 2024 | 69.62% |
| Jun 30, 2024 | 18.06% |
| Mar 31, 2024 | -51.46% |
| Dec 31, 2023 | 19.79% |
| Sep 30, 2023 | 46.98% |
| Jun 30, 2023 | 8.23% |
| Mar 31, 2023 | 4.56% |
| Dec 31, 2022 | -42.59% |
| Sep 30, 2022 | 304.71% |
| Jun 30, 2022 | 25.93% |
| Mar 31, 2022 | -80.88% |
| Dec 31, 2021 | 203.00% |
| Sep 30, 2021 | 42.94% |